Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

NCT ID: NCT00464776

Last Updated: 2011-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31

Brief Summary

This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

Various sequences of 3 doses of Aliskiren plus placebo

Group Type: EXPERIMENTAL

Aliskiren

Intervention Type: DRUG

2

Various sequences of 3 doses of Aliskiren plus placebo

Group Type: EXPERIMENTAL

Aliskiren

Intervention Type: DRUG

3

Various sequences of 3 doses of Aliskiren plus placebo

Group Type: EXPERIMENTAL

Aliskiren

Intervention Type: DRUG

4

Various sequences of 3 doses of Aliskiren plus placebo

Group Type: EXPERIMENTAL

Aliskiren

Intervention Type: DRUG

Interventions

Aliskiren

Intervention Type: DRUG

Aliskiren

Intervention Type: DRUG

Aliskiren

Intervention Type: DRUG

Aliskiren

Intervention Type: DRUG

Other Intervention Names

SPP100; SPP100; SPP100; SPP100

Eligibility Criteria

Inclusion Criteria

• Male and/or female patients from 30-80 years of age.
• Type 2 diabetes (defined using World Health Organization criteria)
• Incipient or overt nephropathy (urinary albumin excretion 100 but ≤ 2000 mg/day).
• Glomerular filtration rate (GFR) 40ml per minute
• To be eligible for randomization, patients must fulfill the following criteria:

1. Patients on ongoing hypertensive therapy must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105 mm Hg at Visit 3 (Day -1, Period 1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to Visit 2 (Run-in period)

2. Newly diagnosed hypertensive patients must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105 mm Hg at Visit 3 (Day -1, Period 1)

• Female patients must be postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening
• Oral body temperature within the range 35.0-37.5 °C
• Able to provide written informed consent prior to study participation.
• Able to communicate well with the investigator and comply with the requirements of the study.
• Patients must be willing and medically able to discontinue anti-hypertensive treatment or any other medication which is prohibited in the study protocol.
• Patients must be on stable hypoglycemic medications for at least 8 weeks prior to visit 1 (Screening visit).

Exclusion Criteria

• Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol.
• Severe Hypertension Grade 3 WHO classification Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)
• Acetylsalicyclic acid (ASA) treatment >1g/day or regular use of Non steroidal anti-inflammatory drugs (NSAIDs)
• Kidney disease not caused by diabetes or hypertension
• Serum potassium < 3.5 or > 5.1 mEq/L
• GFR < 40 ml/min/1.73m2 as measured by the Modification of Diet in Renal Disease (MDRD) formula
• Serum albumin < 2.0mg/dL
• History of hypertensive encephalopathy or cerebrovascular accident at any time prior to Visit 1
• Transient ischemic cerebral attack during the 6 months prior to Visit 1
• Current diagnosis of heart failure New York Heart Association (NYHA) Class II-IV
• History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1
• Second or third degree heart block without a pacemaker
• Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia
• Clinically significant valvular heart disease
• Type 1 diabetes mellitus
• Uncontrolled Type II diabetes mellitus Hemoglobin subtype A1C (HbA1C) >11 %
• History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years
• Pregnant or nursing women
• Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
• Significant illness within the two weeks prior to dosing.
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:

• History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
• Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1
• Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.
• Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase
• Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt
• Current treatment with cholestyramine or cholestipol resins
• History of immunocompromise, including a positive HIV test result.
• History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
• History of drug or alcohol abuse within the 12 months prior to dosing.
• Persons directly involved in the execution of this protocol.
• Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety
• History of noncompliance to medical regimens or unwillingness to comply with the study protocol
• Known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors and/or to thiazide diuretics or other sulfonamide derived drug
• Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study
• Patients who previously participated in any Aliskiren study.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: lead

Responsible Party

Novartis

Principal Investigators

Novartis

Role: PRINCIPAL_INVESTIGATOR

Investigative site

Locations

Novartis

Gentofte Municipality, , Denmark

Countries

Denmark

References

Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia. 2010 Aug;53(8):1576-80. doi: 10.1007/s00125-010-1789-6. Epub 2010 May 18.

Reference Type: DERIVED

PMID: 20480132 (View on PubMed)

Other Identifiers

CSPP100A2240

Identifier Type: -

Identifier Source: org_study_id